Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma - Seggewiss-Bernhardt R., Bargou R.C., Goh Y.T., Stewart A.K., Spencer A., Alegre A., Bladé J., Ottmann O.G., Fernandez-Ibarra C., Lu H., Pain S., Akimov M., Iyer S.P. (Cancer, 2015)